ClinicalTrials.gg
CompletedNCT03009760Updated Jan 20, 2017

To Investigate Pharmacokinetics and Pharmacodynamics of CJ-12420 After Single and Multiple Dose Administration

A Phase 1 interventional study of CJ-12420 50mg(HP-) and CJ-12420 100mg(HP-) in Healthy, sponsored by HK inno.N Corporation. Completed. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-20.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to compare the pharmacokinetics and pharmacodynamics of CJ-12420 after single and multiple dose administration according to H. pylori infection.

Read the detailed description
  1. Cohort 1: To investigate the pharmacokinetics and pharmacodynamics of CJ-12420 after the multiple dose administration in H. pylori negative volunteers.
  2. Cohort 2: To investigate the pharmacokinetics and pharmacodynamics of CJ-12420 after the single dose administration in H. pylori positive volunteers.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers between 20 to 45 years of age (inclusive)
  • (BMI) in the range of 19\~28 kg/㎡ and weighted at least 50kg
  • Medically healthy with no vital signs (blood pressure in the sitting position, pulse rate)

    • 90 mmHg ≤ systolic blood pressure ≤ 140 mmHg
    • 50 mmHg ≤ diastolic blood pressure ≤ 95 mmHg
    • 45 beats per minute ≤ pulse rate ≤ 95 beats per minute
  • Understood the requirements of the study and voluntarily consented to participate in the study
  • Agreed to be sexually abstinent or to use a condom or spermicide when engaging in sexual activity and not to donate sperm during the course of the study for 30 days following completion of the study
  • Non-smokers or non-users of nicotine-containing products for at least 1 year
  • [Cohort 1] H. pylori negative as determined by urea breath test and serum IgG antibody
  • [Cohort 2] H. pylori positive as determined by urea breath test and serum IgG

Exclusion criteria

Exclusion Criteria:

  • History of gastrointestinal, renal, hepatic, neurologic, hemato-oncologic, endocrine, pulmonary, immunologic, psychiatric, musculoskeletal, or cardiovascular disease or any other condition, which in the opinion of the investigators, would jeopardize the safety of the subject or impact the validity of the study results
  • History of allergy or to any drug, including prior serious adverse reaction to PPIs or P-CABs
  • Undergone surgery or in a medical condition, which in the judgment of the PI or investigators may affect absorption, distribution, metabolism or elimination of the study drug
  • Administered other drug(s) in other clinical study within 60 days prior to screening visit
  • Donated blood within 60 days or blood components within 30 days, or had been transfused plasma within 30 days prior to screening visit
  • On special diet or have experienced substantial changes in eating habits within 30 days prior to screening visit
  • Used any prescription medication within 14 days, or any other OTC medications including herbal products within 7 days prior to screening visit
  • Consumed over 21 units/week of alcohol
  • Consumed over 5 units/day of caffeine-containing beverage
  • Positive urine screen for drugs and/or cotinine
  • Positive blood screen for (HIV), or C, or syphilis
  • Clinically significant abnormalities of liver function tests (≥1.5 fold of normal upper limit in the level of L- (ALT), L-aspartate aminotransferase (AST) or total )
  • Unable to bear pH meter catheter insertion
  • History of symptomatic GERD, erosive esophagitis, duodenal ulcer, gastric ulcer, Barrett's esophagus, or Zollinger-Ellison syndrome
  • Clinically significant observations considered as unsuitable based on medical judgment by investigators
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    CJ-12420 50mg(HP-)

    CJ-12420 50mg in H. pylori negative subject

    Drug: CJ-12420 50mg(HP-)

  • Experimental
    CJ-12420 100mg(HP-)

    CJ-12420 100mg in H. pylori negative subject

    Drug: CJ-12420 100mg(HP-)

  • Experimental
    CJ-12420 50mg(HP+)

    CJ-12420 50mg in H. pylori positive subject

    Drug: CJ-12420 50mg(HP+)

  • Experimental
    CJ-12420 100mg(HP+)

    CJ-12420 100mg in H. pylori positive subject

    Drug: CJ-12420 100mg(HP+)

Interventions

  • CJ-12420 50mg in H. pylori negative subject

    Also known as: not yet determined

  • CJ-12420 100mg in H. pylori negative subject

    Also known as: not yet determined

  • DrugCJ-12420 50mg(HP+)

    Drug page: Tegoprazan

    CJ-12420 50mg in H. pylori positive subject

    Also known as: not yet determined

  • DrugCJ-12420 100mg(HP+)

    Drug page: Tegoprazan

    CJ-12420 100mg in H. pylori positive subject

    Also known as: not yet determined

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax) of CJ-12420

    Time frame: up to 12 hours

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC) of CJ-12420

    Time frame: up to 12 hours

  2. Time of maximum observed concentration(tmax) of CJ-12420

    Time frame: up to 12 hours

  3. Half life(t1/2β) of CJ-12420

    Time frame: up to 12 hours

  4. Mean pH

    Data from the pH probe monitoring

    Time frame: Day -1, Day 1, Day 7 up to 24 hours

  5. Time at pH > 4(%)

    the percent of time the pH as data from the pH probe monitoring

    Time frame: Day -1, Day 1, Day 7 up to 24 hours

  6. Time at pH > 6(%)

    the percent of time the pH as data from the pH probe monitoring

    Time frame: Day -1, Day 1, Day 7 up to 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2016
First posted
Jan 4, 2017
Start
Jan 2015
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Last update
Jan 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03009760
Collaborators
Asan Medical Center
Responsible party
Sponsor
First posted
Jan 4, 2017
Start date
Jan 2015
Primary completion
Apr 2016
Completion
Apr 2016
Last update
Jan 20, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion